← Back to Search

Cancer Vaccine

HER3 Vaccine for Cancer

Phase 1
Recruiting
Research Sponsored by Herbert Lyerly
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Female patients must be of non-child-bearing potential or use effective contraception.
Adequate hematologic function, with ANC >1500/µL, Hemoglobin ≥ 9 g/dL, and Platelets ≥ 75,000/µL.
Must not have
Known CNS/brain metastases
Patients must have recovered to Grade 1 toxicities from any prior treatment(s).
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a vaccine that produces the full length human HER3 protein to target cancers that express the human epidermal growth factor receptor HER3. The objectives of the study are to determine the safety and tolerability of the vaccine and to see if it can cause a HER3 specific immune response in patients.

Who is the study for?
Adults who've had surgery for solid tumors like breast, lung, or prostate cancer and finished their standard treatments can join. They should be in good physical shape (ECOG 0 or 1), have a life expectancy over 3 months, and normal organ function. Women must not be pregnant and use birth control. People with autoimmune diseases, active infections, brain metastases, or recent other cancers aren't eligible.
What is being tested?
The trial is testing pING-hHER3FL—a DNA-based vaccine targeting HER3 protein on cancer cells—given as an injection every four weeks for three doses. It aims to see if it's safe and can trigger the immune system to fight cancer expressing the HER3 protein.
What are the potential side effects?
As this is an investigational vaccine, potential side effects are being studied but may include typical vaccine reactions such as pain at the injection site, fatigue, feverish feelings or chills.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am either not able to have children or I use effective birth control.
Select...
My blood counts meet the required levels for treatment.
Select...
I am fully active or can carry out light work.
Select...
I am 18 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My cancer has spread to my brain.
Select...
I have recovered from side effects of my previous treatments.
Select...
I am not on steroids or other immune-suppressing drugs like azathioprine.
Select...
I do not have an active infection, including HIV or hepatitis.
Select...
I have received immunotherapy before.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Rate of T and B cell activity
Secondary study objectives
Relapse-free survival
Tolerability of pING-hHER3FL

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: TreatmentExperimental Treatment1 Intervention
4 mg pING-hHER3FL ID or IM

Find a Location

Who is running the clinical trial?

Herbert LyerlyLead Sponsor
4 Previous Clinical Trials
33 Total Patients Enrolled

Media Library

pING-hHER3FL (Cancer Vaccine) Clinical Trial Eligibility Overview. Trial Name: NCT03832855 — Phase 1
Cancer Research Study Groups: Treatment
Cancer Clinical Trial 2023: pING-hHER3FL Highlights & Side Effects. Trial Name: NCT03832855 — Phase 1
pING-hHER3FL (Cancer Vaccine) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03832855 — Phase 1
~0 spots leftby Jan 2025